{
  "resourceType" : "MedicationRequest",
  "id" : "mii-exa-onko-tucatinib-option",
  "meta" : {
    "profile" : ["https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-therapieempfehlung-medikation|2027.0.0-ballot.1"]
  },
  "language" : "de",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: MedicationRequest mii-exa-onko-tucatinib-option</b></p><a name=\"de-mii-exa-onko-tucatinib-option\"> </a><a name=\"de-hcmii-exa-onko-tucatinib-option\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-onko-therapieempfehlung-medikation.html\">MII PR Onkologie Therapieempfehlung Medikation</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Option</p><p><b>medication</b>: <span title=\"Codes:{http://fhir.de/CodeSystem/bfarm/atc L01EH03}\">Tucatinib + Trastuzumab + Capecitabin</span></p><p><b>subject</b>: <a href=\"Patient-mii-exa-onko-molecular-board-patient.html\">Maria Müller  Female, DoB: 1968-07-22 ( https://www.medizininformatik-initiative.de/fhir/sid/patienten#MTB-2024-001)</a></p><p><b>authoredOn</b>: 2024-01-16</p><p><b>reasonReference</b>: <a href=\"Condition-primaertumor-example.html\">Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet</a></p><p><b>note</b>: </p><blockquote><div><p>Drittlinien-Kombination für Hirnmetastasen oder mehrfach resistente HER2+ Erkrankung</p>\n</div></blockquote></div>"
  },
  "status" : "active",
  "intent" : "option",
  "medicationCodeableConcept" : {
    "coding" : [{
      "system" : "http://fhir.de/CodeSystem/bfarm/atc",
      "code" : "L01EH03",
      "display" : "Tucatinib"
    }],
    "text" : "Tucatinib + Trastuzumab + Capecitabin"
  },
  "subject" : {
    "reference" : "Patient/mii-exa-onko-molecular-board-patient"
  },
  "authoredOn" : "2024-01-16",
  "reasonReference" : [{
    "reference" : "Condition/primaertumor-example"
  }],
  "note" : [{
    "text" : "Drittlinien-Kombination für Hirnmetastasen oder mehrfach resistente HER2+ Erkrankung"
  }]
}